The blockade of APE1 activity by inhibitors has been demonstrated to induce lethality in breast cancer susceptibility (BRCA)- and ataxia-telangiectasia mutated (ATM)-deficient cells22. The gene discussed is ATM; the disease is breast carcinoma.